English | Español

Novartis
Patient Daily | May 7, 2023

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Patient Daily | May 7, 2023

Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Patient Daily | May 7, 2023

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Patient Daily | May 7, 2023

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
Carol Ostrow | Feb 7, 2019

Novartis says Cosentyx better at clearing skin in psoriasis patients than Stelara
Press release submission | Dec 5, 2018

NOVARTIS: Announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
Press releases submission | May 15, 2018

NOVARTIS: Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
Carrie Bradon | Dec 1, 2017

Novartis announces positive results of MONALEESA-7 trial

Trending
+ Community
Patient Daily | Apr 17, 2025

ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+ Pharmaceuticals
Patient Daily | Apr 17, 2025

UCSF neurosurgeon: 'The idea that 340B is about helping the poor is a fiction'
+ Pharmaceuticals
Patient Daily | Apr 22, 2025

National Consumers League CEO: 340B program abuse is 'a financial bonanza for non-profit hospitals'
+ Pharmaceuticals
Patient Daily | Apr 23, 2025

State Sen. Baldacci: 340B reform ‘could help hospitals alone to the tune of 50 to 70 million per year'